Literature DB >> 7537506

The expressed L1 proteins of HPV-1, HPV-6, and HPV-11 display type-specific epitopes with native conformation and reactivity with neutralizing and nonneutralizing antibodies.

J F Hines1, S J Ghim, N D Christensen, J W Kreider, W A Barnes, R Schlegel, A B Jenson.   

Abstract

Previous studies demonstrated that the human papillomavirus (HPV) type 1 L1 protein, expressed in cos cells by an SV40-based vector, displays conformational epitopes characteristic of native virions. In this study, we analyzed the expression of HPV-1, HPV-6, and HPV-11 L1 proteins in order to determine the forms of conformational epitopes expressed by recombinant L1 proteins. Using both immunofluorescence and immunoprecipitation techniques, polyclonal and monoclonal antibodies (MAbs) generated against native HPV-11 virions reacted with expressed L1 proteins of HPV-6 and/or HPV-11, but not HPV-1. Similarly, polyclonal antibodies and MAbs generated against HPV-1 virions reacted with the expressed L1 protein of HPV-1, but not HPV-6 or HPV-11. Of two MAbs that neutralized HPV-11 infection of murine fetal foreskin xenografts, one reacted with the expressed L1 protein of both HPV-6 and HPV-11, and the other reacted with HPV-11 only. A nonneutralizing conformationally dependent MAb reacted with the expressed L1 protein of both HPV-6 and HPV-11. These results demonstrate that expressed HPV L1 proteins retain type-specific, neutralizing, and nonneutralizing conformational epitopes and that cos cells may be utilized to evaluate host immune responses to such epitopes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7537506     DOI: 10.1159/000163906

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  5 in total

1.  Human papillomavirus infection.

Authors:  J F Hines; S J Ghim; A B Jenson
Journal:  BMJ       Date:  1996-03-02

Review 2.  Immunomanipulative strategies for the control of human papillomavirus associated cervical disease.

Authors:  R W Tindle
Journal:  Immunol Res       Date:  1997       Impact factor: 4.505

3.  Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.

Authors:  Stephanie M Bywaters; Sarah A Brendle; Kerstin P Tossi; Jennifer Biryukov; Craig Meyers; Neil D Christensen
Journal:  Viruses       Date:  2017-11-10       Impact factor: 5.048

4.  A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil).

Authors:  Vandana A Govan
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

5.  Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas.

Authors:  Vandana A Govan; Edward P Rybicki; Anna-Lise Williamson
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.